GHRP-6 — Research Dossier
Evidence grading
Class
GHS-R1a agonist
Original synthetic GHRP; Bowers et al. 1984
Role in drug discovery
Template for MK-677
Screening pharmacophore for non-peptide GHS class
Appetite effect
Strong (orexigenic)
Strongest hunger response among traditional GHRPs
FDA approval
None
Not approved for any indication
GHRP-6 is the prototype hexapeptide GH secretagogue that served as the molecular template for ghrelin's discovery and the development of MK-677 — historically foundational, and characterised primarily by mechanistic and preclinical data outside that pharmacological role.
GHRP-6 is a synthetic hexapeptide GH secretagogue acting at the ghrelin receptor (GHS-R1a), one of the original GHRPs characterised by Bowers and colleagues. Its pharmacology was so central to the field that it served as the screening template for the discovery of endogenous ghrelin and for the development of non-peptide secretagogues, culminating in MK-677. Among the traditional GHRPs it is noted for a particularly strong appetite-stimulating effect.
A substantial body of work by Berlanga-Acosta and colleagues documents cytoprotective and tissue-protective effects — cardiac, hepatic, and against ischaemic and inflammatory injury — in animal models, representing a distinct research strand from its GH-secretagogue pharmacology.
“GHRP-6 served as the central pharmacological template for the discovery of endogenous ghrelin and the development of the non-peptide growth hormone secretagogue class, including MK-677.”
— Smith RG et al., Science 1993
Mechanism
GHRP-6 activates GHS-R1a to stimulate pulsatile GH release and antagonise somatostatin. Its defining clinical signature among the GHRPs is potent orexigenic activity — the strongest hunger response in the traditional GHRP class — mediated via hypothalamic NPY/AgRP pathways. Unlike ipamorelin and GHRP-2, it elevates cortisol and prolactin, reducing hormonal selectivity. Its role as the screening pharmacophore for ghrelin discovery and non-peptide GHS development (L-692,429 → L-692,585 → MK-677) is foundational to the field.
Clinical evidence base
GH release (established)
GHRP-6 is an effective GH releaser in animals and humans, confirmed across the foundational Bowers-era pharmacology literature from the 1980s and subsequent comparative studies.
Human safety (early-phase)
Berlanga-Acosta et al. reported that intravenous GHRP-6 was safe in a dose-escalation clinical trial in healthy volunteers and found no adverse pharmacological interaction with the beta-blocker metoprolol — early but genuine human safety data establishing the compound's tolerability profile.
Cytoprotection (preclinical)
The modern GHRP-6 literature is predominantly preclinical, exploring cardioprotection and cytoprotection in ischaemia, inflammatory, and hepatotoxicity models rather than approved therapeutic endpoints. These findings have not been replicated in controlled human efficacy trials.
Regulatory status and evidence grade
GHRP-6 is not approved by the FDA, MHRA, or EMA for any indication. As a GH secretagogue it falls under WADA category S2 (prohibited). Material supplied for laboratory work is research-use only.
Evidence grade: Phase I–II. GH-releasing activity and early human safety are documented, and the compound's historical role in drug discovery is significant. The cytoprotective evidence base is predominantly preclinical, with no registrational efficacy trials completed.
See also
References
- 1
Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984.
- 2
Smith RG, Pong SS, Hickey G, et al. Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Science. 1993.
- 3
Berlanga-Acosta J, Guillén-Nieto G, Rodríguez-Rodríguez N, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Cardiol. 2017.
- 4
Deghenghi R, Cananzi MM, Torsello A, et al. GH-releasing activity of hexarelin and related peptides in the rat. Life Sci. 1994.
Research & Laboratory Use Only
This dossier is compiled for research planning and educational purposes only. It summarises published scientific literature and does not constitute medical advice, dosing guidance, or a therapeutic claim. All Nexyra Lab products are for research purposes only and are not for human or veterinary use. Nothing in this document should be interpreted as recommending, endorsing, or facilitating the self-administration of any compound.
A one-time legal review of this template and disclaimer is recommended before the Journal section is made publicly accessible, given the health-adjacent nature of this content.
